Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) Products: A Manual for Drug Regulatory Authorities - Regulatory Support Series No. 005
(1998; 213 pages)
Table of Contents
View the documentPREFACE
View the documentI. INTRODUCTION
Open this folder and view contentsII. PROVISIONS AND PREREQUISITES FOR REGULATORY CONTROL
Open this folder and view contentsIII. OPERATING ACTIVITIES
Open this folder and view contentsIV. REVIEW OF APPLICATIONS FOR MARKETING AUTHORIZATION OF MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
View the documentV. ISSUE OF WRITTEN MARKETING AUTHORIZATION
View the documentVI. VARIATIONS
View the documentVII. PERIODIC REVIEWS
View the documentVIII. SUSPENSION AND REVOCATION OF MARKETING AUTHORIZATION
View the documentGLOSSARY
View the documentABBREVIATIONS
View the documentREFERENCES
Close this folderANNEXES
Close this folderAnnex 1: National drug regulatory legislation: guiding principles for small drug regulatory authorities1
View the document1. Introduction
View the document2. Drafting national legislation: points for consideration
View the document3. Defining the scope of the marketing authorization procedure for medicinal products
Close this folder4. Example of a legislative scheme for regulating medicinal products.
View the document4.1 General considerations
Close this folder4.2 Model Legislative text and commentary (in italics)
View the documentI. Administration
View the documentII. Provisional registration/marketing authorization and inventory of medicinal products
View the documentIII. Screening of products and issuance of product licences/authorizations
View the documentIV. Other activities requiring authorization/licensing
View the documentV. General provisions
View the documentVI. Interpretation
View the documentAppendix 1. Example of a legislation scheme for registration of pharmacy personnel
View the documentAppendix 2. Guidelines, documents and other regulatory instruments established by WHO to support drug regulatory authorities
View the documentAppendix 3. References and selected bibliography
Open this folder and view contentsAnnex 2: *Guidelines for Implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce1
Open this folder and view contentsAnnex 3: *Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability1
View the documentAnnex 4: Model Guidelines on Conflict of Interest and Model Proforma for a Signed Statement on Conflict of Interest
View the documentAnnex 5: Model Contract between a Regulatory Authority and an External Evaluator of Chemistry, Pharmaceutical and Bioavailability Data
View the documentAnnex 6: Model Application Form for new Marketing Authorizations, Periodic Reviews and Variations, with Notes to the Applicant
View the documentAnnex 7: Detailed Advice on Evaluation of Data by the Drug Regulatory Authority
Open this folder and view contentsAnnex 8: Ethical criteria for medicinal drug promotion1
View the documentAnnex 9: Model marketing authorization letter
View the documentAnnex 10: Model List of Variations (Changes) to Pharmaceutical Aspects of Registered Products which may be made without Prior Approval
Open this folder and view contentsAnnex 11: *Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms1
 
VI. Interpretation

22. The Legislation should include an interpretation of terms which may be used in a special context. In this model text given here, terms which might need interpretation include:

“Appointed date” means the date specified under section 5 (1) of the Law;

“Inventory” refers to the listing of provisionally registered/authorized medicinal products under section 5 (2) of the Law;

“Medicinal product” means any medicine intended for human or veterinary use, presented in its finished dosage form or as a starting material for use in such dosage form;

“Minister” means the Minister responsible for matters relating to medicinal products;

“Person” includes a natural person as well as a body corporate, partnership or association of persons, and establishments such as hospital pharmacies, clinics, and health centres storing or distributing medicinal products;

“Provisionally authorized/registered” is used in relation to a medicinal product which has been listed in the inventory under section 5 of the Law and which has not been screened for purposes of a product licence/marketing authorization under sections 6 and 9 of the Law;

“Register” means the register of medicinal products for which a product licence/marketing authorizaton has been issued in terms of sections 6 and 9 of the Law or the register of persons, i.e. the pharmacist and pharmacy assistant;

“Sell” means to sell for cash or on credit or by way of exchange and whether by wholesale or retail and “sale” shall have a corresponding meaning.

The above are some of the more important terms used in the legislative scheme which need to be defined. But other terms can also be defined. The WHO text on Good Manufacturing Practices for Pharmaceutical Products contains a number of definitions of terms such as “manufacture” which can be included, after adaptation, if necessary, in the definition section.

to previous section to next section
 

Last updated: April 24, 2012